Unknown

Dataset Information

0

Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.


ABSTRACT: The V600E mutation of B-Raf kinase results in constitutive activation of the MAPK signaling pathway and is present in approximately 7% of all cancers. Using structure-based design, a novel series of pyrazolopyridine inhibitors of B-Raf(V600E) was developed. Optimization led to the identification of 3-methoxy pyrazolopyridines 17 and 19, potent, selective, and orally bioavailable agents that inhibited tumor growth in a mouse xenograft model driven by B-Raf(V600E) with no effect on body weight. On the basis of their in vivo efficacy and preliminary safety profiles, 17 and 19 were selected for further preclinical evaluation.

SUBMITTER: Wenglowsky S 

PROVIDER: S-EPMC4017973 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4160747 | biostudies-literature
| S-EPMC4789661 | biostudies-literature
| S-EPMC7812606 | biostudies-literature
| S-EPMC10363616 | biostudies-literature
| S-EPMC5949730 | biostudies-literature
| S-EPMC4948009 | biostudies-literature
| S-EPMC8392731 | biostudies-literature
| S-EPMC8201761 | biostudies-literature
| S-EPMC3427755 | biostudies-literature
| S-EPMC2596069 | biostudies-literature